A post-marketing large-scale study of prazosin GITS for the treatment of hypertension in private practice

Indian Heart Journal

Volumn 48, Issue SUPPL. 1, 1996, Pages 46-50

  Joglekar, S J ^a   Troy, S ^b  

^a PFIZER INC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PRAZOSIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG TOLERANCE; HUMAN; HYPERTENSION; HYPOTENSION; IMPOTENCE; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; SUSTAINED RELEASE PREPARATION; SYNCOPE; SYSTOLIC BLOOD PRESSURE;

EID: 0029837582     PISSN: 00194832     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Memorandum d'une reunion OMS/SIM. Medicine et hygiene 1990 (April): 1274-1282
2. Gardener MJ, Altman DG. Statistics with confidence. London: BMJ, 1989; 18-19
3. Neaton JD, Grimm RH, Prineas RJ, et al. Treatment Of Mild Hypertension Study. Final results. JAMA 1993; 14: 143-158
4. Leren P, Foss PO, Helgeland A, et al. Effect of propranolol and prazosin on blood lipids. The Oslo study. Lancet 1980; 2: 4-6.
5. Goto Y. Selective alpha-1 inhibition and clinical management of hypertension with consideration of coronary heart disease risk factors: results of a multicenter trial in Japan. Clin Thera 1987; 9 (Suppl D): 46-57
6. Pollare T, Lithell H, Selinus I, Berne C. Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia 1988, 31: 415-420